Dynamics of cognitive change in HIV‐infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study
Authors:
- A WinstonAWA Winston
- S EmerySES Emery
- the Altair Study GroupTGthe Altair Study Group
- 12 December 2011
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 13 (4) , 245-251
Abstract
Background Improvements in neurocognitive (NC) function have been associated with commencing antiretroviral therapy in HIV-infected subjects. However, the dynamics of such improvements are poorly understood. Methods We assessed changes in NC function via a validated computerized battery (CogState T, Melbourne, Victoria, Australia) at baseline and after 24 and 48 weeks in a subset of therapy-naive neuro-asymptomatic HIV-infected subjects, randomized to commence three different antiretroviral regimens. Results Of 28 subjects enrolled in the study, nine, eight and 11 were randomly allocated to commence tenofovir/emtricitabine with efavirenz (arm 1), atazanavir/ritonavir (arm 2) and zidovudine/abacavir (arm 3), respectively. Overall improvements in NC function were observed at week 24 and function continued to improve at week 48 (changes in z-score for overall cognitive global score of 0.16 and 0.18 at weeks 24 and 48, respectively). Within the NC speed domains, generally greater improvements were observed in arms 2 and 3, compared with arm 1 (changes in z-score for composite speed scores at weeks 24/48 of 0.16/0.16, -0.29/-0.24 and -0.15/-0.31 in arms 1, 2 and 3, respectively; P = 0.04 for change at week 48 in arm 3 versus arm 1). Finally, improvements in executive function occurred later (only observed at week 48) and were driven by improvements in arm 3 (z-score changes of 0.23, 0.06 and -0.78 in arms 1, 2 and 3, respectively; P = 0.02 for change in arm 3 versus arm 1). Conclusion Improvements in NC function continue over the first year after initiating antiretroviral therapy in neuro-asymptomatic HIV-infected subjects.Keywords
This publication has 17 references indexed in Scilit:
- Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment–Naive, HIV‐Infected Subjects: Week 48 Data from the Altair StudyClinical Infectious Diseases, 2010
- Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment‐Naive, HIV‐1–Infected Individuals Commencing cART? A Randomized, Controlled StudyClinical Infectious Diseases, 2010
- Correlations between Computerized Battery Testing and a Memory Questionnaire for Identification of Neurocognitive Impairment in HIV Type 1-Infected Subjects on Stable Antiretroviral TherapyAIDS Research and Human Retroviruses, 2009
- HIV Infection of the Central Nervous System: Clinical Features and NeuropathogenesisNeurologic Clinics, 2008
- Updated research nosology for HIV-associated neurocognitive disordersNeurology, 2007
- The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test batteryArchives of Clinical Neuropsychology, 2006
- Prediction of Neuropsychiatric Adverse Events Associated with Long-Term Efavirenz Therapy, Using Plasma Drug Level MonitoringClinical Infectious Diseases, 2005
- Longitudinal Improvement in Psychomotor Processing Speed Is Associated With Potent Combination Antiretroviral Therapy in HIV-1 InfectionThe Journal of Neuropsychiatry and Clinical Neurosciences, 2003
- The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test–retest intervalsJournal of the International Neuropsychological Society, 2003
- Safety and Tolerance of Efavirenz in Different Antiretroviral Regimens: Results from a National Multicenter Prospective Study in 1,033 HIV-Infected PatientsHIV Research & Clinical Practice, 2002